Doan, Alexander E.
Mueller, Katherine P. http://orcid.org/0000-0002-1873-3638
Chen, Andy Y. http://orcid.org/0000-0002-5018-355X
Rouin, Geoffrey T.
Chen, Yingshi http://orcid.org/0000-0002-5391-5103
Daniel, Bence http://orcid.org/0000-0002-2410-8767
Lattin, John
Markovska, Martina
Mozarsky, Brett
Arias-Umana, Jose http://orcid.org/0000-0002-7154-4780
Hapke, Robert
Jung, In-Young
Wang, Alice http://orcid.org/0000-0002-1789-8561
Xu, Peng
Klysz, Dorota http://orcid.org/0000-0002-6733-6110
Zuern, Gabrielle
Bashti, Malek http://orcid.org/0000-0003-0398-3367
Quinn, Patrick J. http://orcid.org/0000-0002-4406-727X
Miao, Zhuang
Sandor, Katalin http://orcid.org/0000-0003-2892-4865
Zhang, Wenxi
Chen, Gregory M.
Ryu, Faith
Logun, Meghan http://orcid.org/0000-0002-7274-811X
Hall, Junior
Tan, Kai
Grupp, Stephan A.
McClory, Susan E.
Lareau, Caleb A. http://orcid.org/0000-0003-4179-4807
Fraietta, Joseph A. http://orcid.org/0000-0001-7900-8993
Sotillo, Elena http://orcid.org/0000-0002-3993-1932
Satpathy, Ansuman T. http://orcid.org/0000-0002-5167-537X
Mackall, Crystal L. http://orcid.org/0000-0001-6323-4304
Weber, Evan W. http://orcid.org/0000-0001-5039-2899
Article History
Received: 12 April 2023
Accepted: 12 March 2024
First Online: 10 April 2024
Change Date: 23 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-024-07450-9
Competing interests
: C.A.L. is a consultant to Cartography Biosciences. S.A.G. receives research funding from Novartis, Kite, Vertex and Servier; consults for Novartis, Roche, GSK, Humanigen, CBMG, Eureka, Janssen/JNJ and Jazz Pharmaceuticals; and has advised for Novartis, Adaptimmune, TCR2, Cellctis, Juno, Vertex, Allogene, Jazz Pharmaceuticals and Cabaletta. J.A.F. receives research funding from Tceleron (formerly Tmunity Therapeutics) and Danaher Corporation; consults for Retro Biosciences; and is a member of the scientific advisory boards of Cartography Biosciences and Shennon Biotechnologies. A.T.S. is a founder of Immunai and Cartography Biosciences and receives research funding from Allogene Therapeutics and Merck Research Laboratories. C.L.M. is a co-founder of and holds equity in Link Cell Therapies, Cargo Therapeutics (formerly Syncopation Life Sciences) and Lyell Immunopharma; holds equity and consults for Mammoth and Ensoma; consults for Immatics and Nektar; and receives research funding from Tune Therapeutics. E.W.W. holds equity in Lyell Immunopharma and consults for Umoja Immunopharma. The remaining authors declare no competing interests.